Panacea Life Sciences Holdings, Inc.
Income Statement
| Line Item | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $960.5K | $347.9K | $399.1K | $677.5K | $324.8K | $366.2K | $469.5K |
| Cost of Revenue | $390.3K | $413.6K | $201.2K | $196.3K | $451.9K | $214.0K | $318.9K | $331.5K |
| Gross Profit | $666.2K | $546.9K | $146.6K | $202.8K | $225.6K | $110.8K | $47.3K | $138.0K |
| Gross Margin | 63.1% | 56.9% | 42.1% | 50.8% | 33.3% | 34.1% | 12.9% | 29.4% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $249.0K | $777.1K | $276.7K | $145.2K | $257.4K | $166.6K | $261.5K | $204.7K |
| Operating Income | $-1.1M | $-1.8M | $-1.4M | $-1.1M | $-1.3M | $-1.4M | $-1.4M | $-1.2M |
| Operating Margin | -100.1% | -184.1% | -406.5% | -269.1% | -190.4% | -423.5% | -379.2% | -264.1% |
| Interest Expense | $429.7K | $412.2K | $396.6K | $366.9K | $380.2K | $379.0K | $597.9K | $570.0K |
| Pretax Income | $-1.4M | $-2.2M | $-2.2M | $-1.9M | $-1.8M | $-1.7M | $-2.7M | $-2.0M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-1.4M | $-2.2M | $-2.2M | $-1.9M | $-1.8M | $-1.7M | $-2.7M | $-2.0M |
| Net Margin | -136.9% | -230.0% | -618.4% | -467.1% | -264.4% | -524.8% | -735.5% | -417.9% |
| EPS (Basic) | $-0.09 | $-0.12 | $-0.13 | $-0.11 | $-0.12 | $-0.15 | $-0.18 | $-0.13 |
| EPS (Diluted) | $-0.09 | $-0.12 | $-0.13 | $-0.11 | $-0.12 | $-0.12 | $-0.18 | $-0.13 |
| Shares Outstanding (Basic) | 16.5M | 16.6M | 16.6M | 17.6M | 15.0M | 14.9M | 14.9M | 15.0M |
| Shares Outstanding (Diluted) | 16.5M | 16.6M | 16.6M | 17.6M | 15.0M | 14.9M | 14.9M | 15.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |